How will you mitigate the risk in IPF drug development?
In idiopathic pulmonary fibrosis (IPF), a chronic and progressive restrictive lung disease, a decline in forced vital capacity (FVC) is used as a primary endpoint in clinical trial. As IPF is a restrictive lung disease, lung diffusion measurements like DLCO and TLCO are needed to monitor drug efficacy. The importance of accurate data collection is critical to demonstrating drug effectiveness in clinical trial.
ACHIEVE THE HIGHEST DATA QUALITY AND REDUCE VARIABILITY
ERT has partnered with sponsors in over 1000 drug development studies. Our lung function testing devices, workflow-driven software, and quality services ensure your trial’s spirometry quality and overall site performance and mitigates the risks in IPF drug development. ERT offers an integrated solution to measure lung function endpoints, using integrated devices and software to measure FVC.
Experts in Respiratory Solutions
LEARN MORE ABOUT HOW ERT CAN SUPPORT YOUR CLINICAL TRIAL with an integrated solution
Collects respiratory patient questionnaires for real-time insights into patient safety and study performance.
Captures, reads, and stores ECGs centrally to avoid the risk of false or inaccurate data.
Measures and analyzes imaging endpoints like chest computed tomography (CT) to provide on-demand evidence of drug safety and efficacy.
Attain actionable insights to increase study power and reduce variability
Take your spirometry to the next level with our smart, portable, and affordable spirometer.
Minimize risk and uncertainty with our centralized spirometry, ECG, patient -reported outcomes and multi-endpoint platform.
Obtain Lung Clearance Index to detect disease progression of early lung disease more accurately.
Centralize your DLCO data collection and analysis to ensure data quality in your clinical trial.
Make home monitoring easy with our integrated home spirometer and electronic diary.
A home spirometry sensor in conjunction with the iSpiro App collects full spirometry at home.